Pasar al contenido principal

ESTUDIO DE LA RELACION ENTRE NEUROINFLAMACION Y EPILEPSIA: EL CASO DE LA ENFERMEDAD DE LAFORA

PID2020-112972RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

P-Rex1 is a novel substrate of the E3 ubiquitin ligase Malin associated with Lafora disease

  • Kumarasinghe, L.
  • Ramirez, J.
  • Mayor, U.
  • Zugaza, J.L.
  • Sanz, P.
  • García-Gimeno, María Adelaida|||0000-0002-6483-3912
[EN] Laforin and Malin are two proteins that are encoded by the genes EPM2A and EPM2B, respectively. Laforin is a glucan phosphatase and Malin is an E3-ubiquitin ligase, and these two proteins function as a complex. Mutations occurring at the level of one of the two genes lead to the accumulation of an aberrant form of glycogen meant to cluster in polyglucosans that go under the name of Lafora bodies. Individuals affected by the appearance of these polyglucosans, especially at the cerebral level, experience progressive neurodegeneration and several episodes of epilepsy leading to the manifestation of a fatal form of a rare disease called Lafora disease (LD), for which, to date, no treatment is available. Despite the different dysfunctions described for this disease, many molecular aspects still demand elucidation. An effective way to unknot some of the nodes that prevent the achievement of better knowledge of LD is to focus on the substrates that are ubiquitinated by the E3-ubiquitin ligase Malin. Some substrates have already been provided by previous studies based on protein-protein interaction techniques and have been associated with some alterations that mark the disease. In this work, we have used an unbiased alternative approach based on the activity of Malin as an E3-ubiquitin ligase. We report the discovery of novel bonafide substrates of Malin and have characterized one of them more deeply, namely PIP3-dependent Rac exchanger 1 (P-Rex1). The analysis conducted upon this substrate sets the genesis of the delineation of a molecular pathway that leads to altered glucose uptake, which could be one of the origin of the accumulation of the polyglucosans present in the disease., This work has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement 813599 (TRIM-NET). We also want to acknowledge the support of the grant from the National Institutes of Health P01 NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), and a grant from la Fundacio La Marato TV3 (202032), to PS; and a grant from the Spanish Ministry of Science and Innovation PID2020-112972RB-I00 to PS and MGG.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pharmacological Modulation of Glutamatergic and Neuroinflammatory Pathways in a Lafora Disease Mouse Model

  • Mollá, Belén
  • Heredia, Miguel
  • Campos, Ángela
  • Sanz, Pascual
15 páginas, 7 figuras, 1 tabla., Lafora disease (LD) is a fatal rare neurodegenerative disorder that affects young adolescents and has no treatment yet. The hallmark of LD is the presence of polyglucosan inclusions (PGs), called Lafora bodies (LBs), in the brain and peripheral tissues. LD is caused by mutations in either EPM2A or EPM2B genes, which, respectively, encode laforin, a glucan phosphatase, and malin, an E3-ubiquitin ligase, with identical clinical features. LD knockout mouse models (Epm2a - / - and Epm2b - / -) recapitulate PG body accumulation, as in the human pathology, and display alterations in glutamatergic transmission and neuroinflammatory pathways in the brain. In this work, we show the results of four pre-clinical trials based on the modulation of glutamatergic transmission (riluzole and memantine) and anti-neuroinflammatory interventions (resveratrol and minocycline) as therapeutical strategies in an Epm2b - / - mouse model. Drugs were administered in mice from 3 to 5 months of age, corresponding to early stage of the disease, and we evaluated the beneficial effect of the drugs by in vivo behavioral phenotyping and ex vivo histopathological brain analyses. The behavioral assessment was based on a battery of anxiety, cognitive, and neurodegenerative tests and the histopathological analyses included a panel of markers regarding PG accumulation, astrogliosis, and microgliosis. Overall, the outcome of ameliorating the excessive glutamatergic neurotransmission present in Epm2b - / - mice by memantine displayed therapeutic effectiveness at the behavioral levels. Modulation of neuroinflammation by resveratrol and minocycline also showed beneficial effects at the behavioral level. Therefore, our study suggests that both therapeutical strategies could be beneficial for the treatment of LD patients. A mouse model of Lafora disease (Epm2b-/-) was used to check the putative beneficial effect of different drugs aimed to ameliorate the alterations in glutamatergic transmission and/or neuroinflammation present in the model. Drugs in blue gave a more positive outcome than the rest., Open Access funding provided thanks to the CRUECSIC agreement with Springer Nature. This work was supported by a grant from the Spanish Ministry of Science and Innovation PID2020-112972RB-I00, an intramural grant ACCI2020 from CIBERER, and a grant from the National Institutes of Health P01NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), to P.S., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

TNF and IL6/Jak2 signaling pathways are the main contributors of the glia-derived neuroinflammation present in Lafora disease, a fatal form of progressive myoclonus epilepsy

  • Rubio, Teresa
  • Viana, Rosa
  • Moreno-Estellés, Mireia
  • Campos, Ángela
  • Sanz, Pascual
15 páginas, 6 figuras, 1 tabla. Supplementary data to this article can be found online at https://doi. org/10.1016/j.nbd.2022.105964., Lafora disease (LD; OMIM#254780) is a rare form of progressive myoclonus epilepsy (prevalence <1:1,000,000) characterized by the accumulation of insoluble deposits of aberrant glycogen (polyglucosans), named Lafora bodies, in the brain but also in peripheral tissues. LD is the most severe form of the group of progressive myoclonus epilepsies, since patients present a rapid deterioration and dementia with amplification of seizures, leading to death after a decade from the onset of the first symptoms. We have recently described that reactive glia-derived neuroinflammation should be considered a novel hallmark of LD since we observed a florid upregulation of differentially expressed genes in both LD mouse lines, which were mainly related to mediators of inflammatory response. In this work, we define an upregulation of the expression of mediators of the TNF and IL6/JAK2 signaling pathways in LD. In addition, we describe the activation of the non-canonical form of the inflammasome. Furthermore, we describe the infiltration of peripheral immune cells in the brain parenchyma, which could aggravate glia-derived neuroinflammation. Finally, we describe CXCL10 and S100b as blood biomarkers of the disease, which will allow the study of the progression of the disease using serum blood samples. We consider that the identification of these initial inflammatory changes in LD will be very important to implement possible anti-inflammatory therapeutic strategies to prevent the development of the disease., This work was supported by a grant from the Spanish Ministry of Science and Innovation PID2020-112972RB-I00, an intramural grant ACCI2020 from CIBERER, a grant from la Fundacio ´ La Marato ´ TV3 (202032), and a grant from the National Institutes of Health P01NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), to P.S., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Age-Related microRNA Overexpression in Lafora Disease Male Mice Provides Links between Neuroinflammation and Oxidative Stress

  • Romá-Mateo, Carlos
  • Lorente-Pozo, Sheila
  • Marquez-Thibaut, Lucia
  • Moreno-Estellés, Mireia
  • Garcés, Concepción
  • González, Dayme
  • Lahuerta, Marcos
  • Aguado, Carmen
  • García-Giménez, José Luis
  • Sanz, Pascual
  • Pallardó, Federico V.
10 páginas, 3 figuras, 1 tabla., Lafora disease is a rare, fatal form of progressive myoclonus epilepsy characterized by continuous neurodegeneration with epileptic seizures, characterized by the intracellular accumulation of aberrant polyglucosan granules called Lafora bodies. Several works have provided numerous evidence of molecular and cellular alterations in neural tissue from experimental mouse models deficient in either laforin or malin, two proteins related to the disease. Oxidative stress, alterations in proteostasis, and deregulation of inflammatory signals are some of the molecular alterations underlying this condition in both KO animal models. Lafora bodies appear early in the animal's life, but many of the aforementioned molecular aberrant processes and the consequent neurological symptoms ensue only as animals age. Here, using small RNA-seq and quantitative PCR on brain extracts from laforin and malin KO male mice of different ages, we show that two different microRNA species, miR-155 and miR-146a, are overexpressed in an age-dependent manner. We also observed altered expression of putative target genes for each of the microRNAs studied in brain extracts. These results open the path for a detailed dissection of the molecular consequences of laforin and malin deficiency in brain tissue, as well as the potential role of miR-155 and miR-146a as specific biomarkers of disease progression in LD., This work was supported by a grant from the Spanish Ministry of Science and Innovation PID2020-112972RB-I00, an intramural grant ACCI2020 from CIBERER, a grant from la Fundació La Marató TV3 (202032), and a grant from the National Institutes of Health P01NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), to P.S.; C.G. was funded by Spanish Ministry of Universities by fellowship FPU18/03969., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deciphering the polyglucosan accumulation present in Lafora disease using an astrocytic cellular model

  • Moreno-Estellés, Mireia
  • Campos, Ángela
  • Rubio-Villena, Carla
  • Kumarasinghe, Lorena
  • García-Gimeno, María Adelaida
  • Sanz, Pascual
This article belongs to the Collection Feature Papers in Molecular Pathology, Diagnostics, and Therapeutics., Lafora disease (LD) is a neurological disorder characterized by progressive myoclonus epilepsy. The hallmark of the disease is the presence of insoluble forms of glycogen (polyglucosan bodies, or PGBs) in the brain. The accumulation of PGBs is causative of the pathophysiological features of LD. However, despite the efforts made by different groups, the question of why PGBs accumulate in the brain is still unanswered. We have recently demonstrated that, in vivo, astrocytes accumulate most of the PGBs present in the brain, and this could lead to astrocyte dysfunction. To develop a deeper understanding of the defects present in LD astrocytes that lead to LD pathophysiology, we obtained pure primary cultures of astrocytes from LD mice from the postnatal stage under conditions that accumulate PGBs, the hallmark of LD. These cells serve as novel in vitro models for studying PGBs accumulation and related LD dysfunctions. In this sense, the metabolomics of LD astrocytes indicate that they accumulate metabolic intermediates of the upper part of the glycolytic pathway, probably as a consequence of enhanced glucose uptake. In addition, we also demonstrate the feasibility of using the model in the identification of different compounds that may reduce the accumulation of polyglucosan inclusions., This work was supported by a grant from the Spanish Ministry of Science and Innovation PID2020-112972RB-I00, a grant from la Fundació La Marató TV3 (202032), and a grant from the National Institutes of Health P01NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), to P.S., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Tesis doctoral (DoctoralThesis)

Búsqueda y caracterización de sustratos fisiológicos de malina, la E3-ubiquitin ligasa implicada en la enfermedad de Lafora

  • Kumarasinghe, Lorena
Tesis doctoral, 123 páginas, en ingles y en español, [EN] Lafora disease (LD) is a rare genetic disease that mainly affects adolescents and belongs to the group of diseases known as Progressive Myoclonus Epilepsies (PMEs). It is a fatal form of progressive myoclonus epilepsy and has an incidence of less than 4 cases in a million people worldwide. LD is caused by the accumulation of aberrant glycogen-like inclusions known as Lafora bodies (LBs), which are present in several tissues but are predominantly found in the brain. These LBs are insoluble and their aggregation leads to cellular toxicity, generating several progressive neurological symptoms, including difficult-to-control seizures, myoclonus, ataxia, dementia, and other symptoms. There is currently no definitive cure for LD, and treatment is mainly symptomatic and supportive, focusing on controlling seizures and managing other symptoms as they arise. The disease is caused by mutations that fall onto genes that codify for two different proteins: Laforin and Malin. These proteins have different functions but work in complex with each other. My Ph.D. studies focused especially on Malin, known to be an E3 ubiquitin ligase which plays a major role in a process called ubiquitination. Therefore, Malin’s activity makes LD a disease connected to the ubiquitin system. Several substrates of Malin have been identified to date, including those involved in the accumulation of polyglucosans, impairment in the degradation processes at the level of the proteasome and autophagy, alteration of glutamatergic transmission and mitochondrial dysfunction. However, many molecular mechanisms leading to these conditions need further elucidation. The hunt for novel substrates could help to identify previously unidentified dysfunctions of Lafora disease and to gain a better understanding of the aforementioned pathophysiological alterations. A proteomic analysis using the bioUb strategy identified 88 differentially ubiquitinated potential candidates involved in protein folding, heat shock response, and regulation of mitochondrial function. Two proteins, P-Rex1 and Hsp90α, were chosen for further study due to their high ubiquitination rate and/or unique peptide number in the proteomic analysis. In this thesis, evidence will be reported in demonstrating how the first substrate is related to LD. We have validated the Malin-dependent ubiquitination of P-Rex1 and have focused on the effect of Malin on the function of P-Rex1 as a guanine-nucleotide exchange factor (GEF) in activating Rac1 GTPase and in increasing glucose uptake. The analysis conducted upon this substrate sets the genesis of the delineation of a molecular pathway that leads to altered glucose uptake, which could be one of the origins of the accumulation of the polyglucosans present in the disease. Experiments conducted for Hsp90α have validated it as a substrate of Malin, not only when it is overexpressed but also at endogenous level and, further on, we have hypothesized how it could possibly be related to the disease., [ES] La enfermedad de Lafora es una rara enfermedad genética que afecta principalmente a los adolescentes y pertenece al grupo de enfermedades conocidas como Epilepsias Mioclónicas Progresivas (PME). Es una forma fatal de epilepsia mioclónica progresiva y tiene una incidencia de menos de 4 casos en un millón de personas en todo el mundo. La LD es causada por la acumulación de inclusiones aberrantes similares al glucógeno conocidas como cuerpos de Lafora (LB), que están presentes en varios tejidos pero se encuentran predominantemente en el cerebro. Estos LB son insolubles y su agregación conduce a la toxicidad celular, generando varios síntomas neurológicos progresivos, que incluyen convulsiones de difícil control, mioclonías, ataxia, demencia y otros síntomas. Actualmente no existe una cura definitiva para la LD, y el tratamiento es principalmente sintomático y de apoyo, centrándose en controlar las convulsiones y manejar otros síntomas a medida que surgen. La enfermedad es causada por mutaciones en genes que codifican para dos proteínas diferentes: Laforin y Malin. Estas proteínas tienen diferentes funciones pero trabajan en forma compleja entre sí. Durante el doctorado, los estudios se centraron especialmente en Malina, conocida por ser una ubiquitina ligasa E3 que desempeña un papel importante en un proceso llamado ubiquitinación. Por lo tanto, la actividad de Malina convierte la enfermedad de Lafora en una enfermedad relacionada con el sistema de ubiquitinación. Se han identificado varios sustratos de Malina hasta ahora, incluidos los implicados en la acumulación de poliglucosanos, deterioro en los procesos de degradación a nivel del proteasoma y autofagia, alteración de la transmisión glutamatérgica y disfunción mitocondrial. Sin embargo, muchos mecanismos moleculares que conducen a estas condiciones necesitan mayor aclaración. La búsqueda de nuevos sustratos podría ayudar a identificar disfunciones de la enfermedad de Lafora no identificadas previamente y a una mayor comprensión de las alteraciones fisiopatológicas descritas anteriormente. Un análisis proteómico utilizando la estrategia bioUb identificó 88 candidatos potenciales diferencialmente ubiquitinados involucrados en el plegamiento de proteínas, la respuesta al choque térmico y la regulación de la función mitocondrial. Se eligieron dos proteínas, P-Rex1 y Hsp90α, para su posterior estudio debido a su alta tasa de ubiquitinación y número de péptido único en el análisis proteómico. En esta tesis, se reportarán evidencias para demostrar cómo el primer sustrato se relaciona con la enfermedad de Lafora. Se ha validado la ubiquitinación de P-Rex1 dependiente de Malina y hemos estudiado como esta modificación altera la actividad de P-Rex1 como factor intercambiador de nucleótidos de guanina (GEF) sobre la GTPasa Rac1 y en la toma de glucosa. El análisis realizado sobre este sustrato establece la génesis de una vía molecular que conduce a la alteración de la captación de glucosa, lo que podría ser uno de los orígenes de la acumulación de los poliglucosanos presentes en la enfermedad. Los experimentos realizados para Hsp90α la han validado como sustrato de Malina y, hemos hipotetizado cómo podría estar relacionada con la enfermedad., Este proyecto ha recibido financiación del Programa de Investigación e Innovación Horizonte 2020 de la Unión Europea bajo el acuerdo de subvención Marie Skłodowska-Curie No 813599, convocatoria H2020- MSCA-ITN-2018 - Innovative Training Networks 2018 del TRIM-NET A training network in drug discovery targeting TRIM ubiquitin ligases. También ha recibido financiación del proyecto PID2020-112972RB-I00 titulado “Estudio de la relación entre neuroinflamación y epilepsia: el caso de le enfermedad de Lafora”, del Programa RETOS del Ministerio de Ciencia e Innovación., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuroinflammation and Epilepsy: From Pathophysiology to Therapies Based on Repurposing Drugs

  • Sanz, Pascual
  • Rubio, Teresa
  • García Gimeno, María Adelaida
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Neuroinflammation and epilepsy are different pathologies, but, in some cases, they are so closely related that the activation of one of the pathologies leads to the development of the other. In this work, we discuss the three main cell types involved in neuroinflammation, namely (i) reactive astrocytes, (ii) activated microglia, and infiltration of (iii) peripheral immune cells in the central nervous system. Then, we discuss how neuroinflammation and epilepsy are interconnected and describe the use of different repurposing drugs with anti-inflammatory properties that have been shown to have a beneficial effect in different epilepsy models. This review reinforces the idea that compounds designed to alleviate seizures need to target not only the neuroinflammation caused by reactive astrocytes and microglia but also the interaction of these cells with infiltrated peripheral immune cells., This research was funded by a grant from the Spanish Ministry of Science and Innovation PID2020-112972RB-I00, a grant from la Fundació La Marató TV3 (202032), and a grant from the National Institutes of Health P01NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), to P.S., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Beneficial Effect of Fingolimod in a Lafora Disease Mouse Model by Preventing Reactive Astrogliosis-Derived Neuroinflammation and Brain Infiltration of T-lymphocytes

  • Rubio, Teresa
  • Campos-Rodríguez, Ángela
  • Sanz, Pascual
16 páginas, 7 figuras, 1 tabla, Lafora disease (LD; OMIM#254780) is a rare, devastating, and fatal form of progressive myoclonus epilepsy that affects young adolescents and has no treatment yet. One of the hallmarks of the disease is the accumulation of aberrant poorly branched forms of glycogen (polyglucosans, PGs) in the brain and peripheral tissues. The current hypothesis is that this accumulation is causative of the pathophysiology of the disease. Another hallmark of LD is the presence of neuroinflammation. We have recently reported the presence of reactive glia-derived neuroinflammation in LD mouse models and defined the main inflammatory pathways that operate in these mice, mainly TNF and IL-6 signaling pathways. In addition, we described the presence of infiltration of peripheral immune cells in the brain parenchyma, which could cooperate and aggravate the neuroinflammatory landscape of LD. In this work, we have checked the beneficial effect of two compounds with the capacity to ameliorate neuroinflammation and reduce leukocyte infiltration into the brain, namely fingolimod and dimethyl fumarate. Our results indicate a beneficial effect of fingolimod in reducing reactive astrogliosis-derived neuroinflammation and T-lymphocyte infiltration, which correlated with the improved behavioral performance of the treated Epm2b-/- mice. On the contrary, dimethyl fumarate, although it was able to reduce reactive astrogliosis, was less effective in preventing neuroinflammation and T-lymphocyte infiltration and in modifying behavioral tests., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by a grant from the Spanish Ministry of Science and Innovation PID2020- 112972RB-I00, a grant from la Fundació La Marató TV3 (202032), and a grant from the National Institutes of Health P01NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), to P.S., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Glial alterations in the glutamatergic and GABAergic signaling pathways in a mouse model of Lafora disease, a severe form of progressive myoclonus epilepsy

  • Viana, Rosa
  • Rubio, Teresa
  • Campos-Rodríguez, Ángela
  • Sanz, Pascual
41 páginas, 13 figuras., Lafora disease (LD; OMIM#254780) is a rare form of progressive myoclonus epilepsy characterized by the accumulation of insoluble deposits of aberrant glycogen (polyglucosans), named Lafora bodies (LBs), in the brain but also in peripheral tissues. It is assumed that the accumulation of LBs is related to the appearance of the characteristic pathological features of the disease. In mouse models of LD, we and others have reported an increase in the levels of reactive astrocytes and activated microglia, which triggers the expression of the different pro-inflammatory mediators. Recently, we have demonstrated that the TNF and IL-6 inflammatory signaling pathways are the main mediators of the neuroinflammatory phenotype associated with the disease. In this work, we present evidence that the activation of these pathways produces a dysregulation in the levels of different subunits of the excitatory ionotropic glutamatergic receptors (phopho-GluN2B, phospho-GluA2, GluK2) and also an increase in the levels of the GABA transporter GAT1 in the hippocampus of the Epm2b-/- mice. In addition, we present evidence of the presence of activated forms of the Src and Lyn protein kinases in this area. These effects may increase the excitatory glutamatergic signaling and decrease the inhibitory GABAergic tone, leading to hyper-excitability. More importantly, the enhanced production of these subunits occurs in non-neuronal cells such as activated microglia and reactive astrocytes, pointing out a key role of glia in the pathophysiology of LD., This work was supported by a grant from the Spanish Ministry of Science and Innovation PID2020-112972RB-I00, a grant from la Fundació La Marató TV3 (202032), a grant from the National Institutes of Health P01NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), to P.S., and a grant from the Prometeo program from Generalitat Valenciana (CIPROM2022/42) to P.S. and R.V., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glial Alterations in the Glutamatergic and GABAergic Signalling Pathways in a Mouse Model of Lafora Disease, a Severe Form of Progressive Myoclonus Epilepsy

  • Viana, Rosa
  • Rubio, Teresa
  • Campos-Rodríguez, Ángela
  • Sanz, Pascual
11 páginas, 5 figuras, Aims: Lafora disease (LD; OMIM#254780) is a rare form of progressive myoclonus epilepsy characterised by the accumulation of insoluble deposits of glycogen in the brain and peripheral tissues. In mouse models of LD, we have identified neuroinflammation as a secondary hallmark of the disease, characterised by increased levels of reactive astrocytes and activated microglia. Our previous work demonstrated that the TNF and IL-6 inflammatory signalling pathways are the primary drivers of this neuroinflammatory phenotype. In this work, we aimed to investigate whether TNF and IL-6 pathway activation contributes to alterations in the glutamatergic and GABAergic signalling pathways. Methods: We performed immunofluorescence and western blot analyses on the hippocampus of a mouse model of LD to evaluate potential changes in proteins associated with glutamatergic and GABAergic signalling pathways. Results: Our findings reveal dysregulation in the expression of subunits of excitatory glutamatergic receptors (phospho-GluN2B and GluK2), as well as an increase in the levels of the GABA transporter GAT1. In addition, we detected activated forms of the Src and Lyn protein kinases in the hippocampus. More importantly, these alterations predominantly occur in nonneuronal cells, such as reactive astrocytes and microglia, underscoring the critical involvement of glial cells in the pathophysiology of LD. Conclusions: The observed upregulation of glutamatergic receptor subunits likely amplifies excitatory glutamatergic signalling, whereas the increased expression of GAT1 may reduce the inhibitory GABAergic tone. These changes contribute to the characteristic hyperexcitability of LD., This work was supported by grants from theSpanish Ministry of Science and Innovation PID2020-112972RB-I00and PID2023-1481023OB-I00; a grant from la Fundació La Marató TV3(202032); a grant from the National Institutes of Health P01NS097197,which established the Lafora Epilepsy Cure Initiative (LECI), to PS;and a grant from the Prometeo program from Generalitat Valenciana(CIPROM2022/42) to P.S. and R.V., Peer reviewed